VALEO PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.115 CAD | +21.05% |
|
-4.17% | -36.11% |
| Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
| Sales 2024 * | 61M 44.59M | Sales 2025 * | 75.83M 55.43M | Capitalization | 11.35M 8.3M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -13.16M | Net income 2025 * | -12M -8.77M | EV / Sales 2024 * | 1.05 x |
| Net Debt 2024 * | 52.53M 38.4M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.15 x |
| P/E ratio 2024 * |
-0.58
x | P/E ratio 2025 * |
-0.88
x | Employees | 100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Valeo Pharma Inc.
More press releases
| 1 day | +21.05% | ||
| 1 week | -4.17% | ||
| Current month | -28.12% | ||
| 1 month | -28.12% | ||
| 3 months | -67.14% | ||
| 6 months | -23.33% | ||
| Current year | -36.11% |
1 week
0.06
0.12
1 month
0.060.17
Current year
0.060.39
1 year
0.060.52
3 years
0.061.22
5 years
0.001.86
10 years
0.001.86
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Pascal Tougas
DFI | Director of Finance/CFO | - | Nov. 19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard MacKay
CHM | Chairman | 89 | 18-07-24 |
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Marc Léger
BRD | Director/Board Member | 65 | 22-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.115 | +21.05% | 259,461 |
| 24-04-25 | 0.095 | +11.76% | 55,240 |
| 24-04-24 | 0.085 | -19.05% | 974,057 |
| 24-04-23 | 0.105 | -4.55% | 98,225 |
| 24-04-22 | 0.11 | -8.33% | 111,100 |
Delayed Quote Toronto S.E., April 26, 2024 at 04:00 pm EDT
More quotes
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
2024-07-03
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.115
CAD
Average target price
0.5
CAD
Spread / Average Target
+334.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.11% | 8.29M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- VPH Stock
